期刊文献+

降脂丸治疗高脂血症54例 被引量:2

Treatment of 54 cases of hyperlipidemia with"Jiangzhi Pill"
下载PDF
导出
摘要 目的观察降脂丸对血脂的影响及其抗氧化作用。方法 54例单纯高脂血症患者服用降脂丸治疗,共4个疗程(56d)。比较治疗前后血脂、肝肾功能、抗氧化指标及不良反应变化。结果治疗后患者肝肾功能及肌酶无明显变化(P>0.05),总胆固醇(TC)、低密度脂蛋白(LDL)显著降低(P<0.05);丙二醛(MDA)明显降低(P<0.05),而谷胱甘肽过氧化物酶(GSH-PX)活性显著提高(P<0.05)。结论降脂丸有较好的降血脂和抗氧化作用。 Objective To study the effects of "Jiangzhi Pill" on blood lipid anti its antioxidation. Methods Fifty-four patients with hyperlipidemia were treated with "Jiangzhi Pill" for four courses. The blood lipids, liver and kidney functions, antioxidant indexes were observed before and after treatment. Results After treat- ment, liver and kidney functions, enzymes were improved little( P 〉0.05 ) ; the TC and LDL were significantly reduced( P 〈0.05 ) ; MDA was decreased while GSH-PX activity was increased(P 〈0.05 ). Conclusion "Jiangzhi Pill" has good results in reducing blood lipid and fighting oxidation.
出处 《上海中医药杂志》 2010年第9期30-31,共2页 Shanghai Journal of Traditional Chinese Medicine
关键词 降脂丸 高脂血症 抗氧化 "Jiangzhi Pill" hyperlipidemia antioxidation
  • 相关文献

参考文献7

二级参考文献37

共引文献3134

同被引文献18

  • 1朱大岭,韩维娜,张荣.细胞色素P_(450)酶系在药物代谢中的作用[J].医药导报,2004,23(7):440-443. 被引量:55
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5230
  • 3USFDA: Guidance {or Industry : Drug Interaction Studies- Study Design, Data Analysis, Implications for Dosing and Labeling[M]. 2006.
  • 4Montastruc F, Sommet A, Bondon-Guitton E, et al. The importance of drug drug interactions as a cause of adverse drug reactions: a pharmacovigi|ance study o{ serotoninergic reuptake inhibitors in France [J]. Eur J Clin Pharmacol, 2012,68(5) :767-775.
  • 5Lynch T, Price A. The effect of eytochrome P450 metabolism on drug response, interactions, and adverse effects [J]. Am Fam Physician, 2007, 76(3):391-396.
  • 6Miller M, Cannon CP, Murphy SA, et at. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial[J]. J Am Coil Cardiol, 2008, 51(7):724 730.
  • 7Gibson DM, Stem RH, Abel RB, et al. Absolute bioavailability of atorvastatin in man[J]. Pharm Res, 1997, 14(2):253.
  • 8Hermann M, Asberg A, Christensen H, et al. Substantially elevated levels of atorvastatin and metabolites in cyclosporine treated renal transplant recipients[J]. Clin Pharmacol Ther, 2004, 76(4) :388 39l.
  • 9Wakelee HA, Takimoto CH, Lopez-Anaya A, et al. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer [J ]. Cancer Chemother Pharmacol,2012,69(2) :563-571.
  • 10闻莉,刘松林,梅国强.高脂血症的中医临床证型分布及辨证规律研究[J].中国中医基础医学杂志,2008,14(3):220-221. 被引量:75

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部